| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2075 | 2017 |
| Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1526 | 2018 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1491 | 2018 |
| Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy V Guadagnino, T Stroffolini, M Rapicetta, A Costantino, LA Kondili, ... Hepatology 26 (4), 1006-1011, 1997 | 472 | 1997 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017 | 308 | 2017 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 303 | 2022 |
| Impact of COVID-19 on global HCV elimination efforts S Blach, LA Kondili, A Aghemo, Z Cai, E Dugan, C Estes, I Gamkrelidze, ... Journal of hepatology 74 (1), 31-36, 2021 | 256 | 2021 |
| Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town G Maio, P D'Argenio, T Stroffolini, A Bozza, L Sacco, ME Tosti, M Intorcia, ... Journal of hepatology 33 (1), 116-120, 2000 | 196 | 2000 |
| Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population LA Kondili, P Chionne, A Costantino, U Villano, CL Noce, F Pannozzo, ... Gut 50 (5), 693-696, 2002 | 140 | 2002 |
| A “systems medicine” approach to the study of non-alcoholic fatty liver disease S Petta, L Valenti, E Bugianesi, G Targher, S Bellentani, F Bonino, ... Digestive and Liver Disease 48 (3), 333-342, 2016 | 79 | 2016 |
| The use of lamivudine for patients with acute hepatitis B (a series of cases) LA Kondili, H Osman, D Mutimer Journal of viral hepatitis 11 (5), 427-431, 2004 | 77 | 2004 |
| Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center LA Kondili, D Genovese, C Argentini, P Chionne, P Toscani, R Fabro, ... European Journal of Clinical Microbiology and Infectious Diseases 25, 527-531, 2006 | 59 | 2006 |
| Hepatitis B virus infection in health care workers in Albania: a country still highly endemic for HBV infection LA Kondili, D Ulqinaku, M Hajdini, M Basho, P Chionne, E Madonna, ... Infection 35, 94-97, 2007 | 54 | 2007 |
| Optimization of hepatitis C virus screening strategies by birth cohort in Italy LA Kondili, I Gamkrelidze, S Blach, A Marcellusi, M Galli, S Petta, M Puoti, ... Liver International 40 (7), 1545-1555, 2020 | 53 | 2020 |
| Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER … LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, ... PLoS One 12 (2), e0172159, 2017 | 53 | 2017 |
| Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, ... Hepatology 66 (6), 1814-1825, 2017 | 49 | 2017 |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study D Razavi-Shearer, I Gamkrelidze, C Pan, J Jia, T Berg, R Gray, YS Lim, ... The Lancet Gastroenterology & Hepatology 8 (10), 879-907, 2023 | 46 | 2023 |
| Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network LA Kondili, GB Gaeta, MR Brunetto, A Di Leo, A Iannone, TA Santantonio, ... PLoS One 12 (10), e0185728, 2017 | 46 | 2017 |
| Impact of the COVID-19 pandemic on hepatitis B and C elimination: an EASL survey LA Kondili, M Buti, M Riveiro-Barciela, M Maticic, F Negro, T Berg, A Craxì JHEP Reports 4 (9), 100531, 2022 | 45 | 2022 |
| Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? LA Kondili, S Robbins, S Blach, I Gamkrelidze, AL Zignego, MR Brunetto, ... Liver International 38 (12), 2190-2198, 2018 | 45 | 2018 |
